Incyte Corporation announced on October 29, 2023, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its investigational drug, INCA033989. This...
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Incyte’s experimental drug, INCA033989, aimed at treating a rare blood cancer known as...
